Status:
NOT_YET_RECRUITING
A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Ovarian Cancer
Recurrent Ovarian Carcinoma
Eligibility:
FEMALE
18+ years
Brief Summary
In ovarian cancer (OC), complete surgical debulking and platinum-based chemotherapy are the standard treatment, now followed by maintenance therapy with PARP inhibitors or Bevacizumab. However, in adv...
Detailed Description
Patients with OC in surveillance after first-line treatment usually have a scheme of clinical visits and serum marker evaluation every three months, associated with alternated transvaginal ultrasound ...
Eligibility Criteria
Inclusion
- Patients with BRCA wild-type, HRP, high-grade serous ovarian cancer
- No residual tumour at first debulking surgery
- More than 6 months since the last platinum-based therapy
Exclusion
- Patients who will not consent to participate in the study
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2027
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT06541171
Start Date
September 1 2024
End Date
August 31 2027
Last Update
August 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universitaro "A. Gemelli" IRCCS
Roma, Italy, 00168